Six-year-old Saffie Sandford from Stevenage, Hertfordshire, has had her sight restored thanks to a life-changing eye gene therapy delivered at Great Ormond Street Hospital (GOSH) in collaboration with researchers at University College London (UCL). The case, announced publicly on April 23, 2026 and continuing to draw international human-interest coverage through the April 26–27 window, marks one of the most encouraging recent examples of how genetic medicine is reaching pediatric patients with rare disorders.
A Rare Inherited Condition With a Narrow Treatment Window
Saffie was diagnosed with Leber’s Congenital Amaurosis (LCA) when she was five and a half years old, after her parents noticed she was struggling to see in the dark. The condition is caused by a mutation in the RPE65 gene that prevents cells in the eye from producing a specific protein essential for normal vision. Babies born with LCA typically have poor sight from infancy that deteriorates over time, with many ultimately losing their vision completely in adulthood. Affected children have reduced vision in daylight and no vision at all in low light.
Without intervention, Saffie’s family was told she would likely have lost her sight entirely by the age of 30.
After initial testing at Moorfields Eye Hospital in London, Saffie was transferred to GOSH for the treatment that has since changed the course of her life.
Luxturna: A One-Time Gene Therapy Delivered Through the NHS
The treatment, marketed under the name Luxturna, is the first of its kind approved for one of the genetic causes of LCA. It works by delivering a healthy copy of the faulty RPE65 gene directly into the eye via injection — a single, one-time procedure for each eye.
Saffie received the gene therapy in her first eye in April 2025, just before her sixth birthday, and in her second eye in September 2025. The therapy was provided through the United Kingdom’s National Health Service.
Her mother, Lisa Sandford, described the diagnosis and the treatment journey in unguarded terms.
“Saffie’s diagnosis came as a huge shock to us, as we’d never heard of the condition or knew me and her dad Tam were carriers,” Lisa said. “It was such a rollercoaster of a journey, but we were so relieved and grateful when we heard there was a treatment available on the NHS for Saffie.”
She described the post-treatment results in equally vivid terms: “Having the gene treatment has been life-changing, it’s like someone waved a magic wand and restored her sight in the dark. We’ve been able to take her trick or treating, and out to restaurants in the evening — something that was impossible before. She’s thriving, and you wouldn’t know she had the condition just by looking at her. The results have been incredible.”
Saffie’s peripheral sight in daylight has also improved. She is now able to see hazards and has shown improvement at school.
Research Confirms the Earlier the Treatment, the Stronger the Outcome
The Sandford family’s story emerged in tandem with new research published by clinicians at GOSH and UCL examining outcomes across a wider patient group. The team studied 15 children, aged 15 months to 12 years, who received Luxturna at GOSH between 2020 and 2023.
Their findings indicated that treating younger children with this gene therapy can improve sight at a critical stage of brain development, strengthening the visual pathways during a window when the brain is still highly adaptable. Older children showed more limited improvements in visual acuity. The research is the first to objectively demonstrate that gene therapy can strengthen visual pathways in young children with this rare eye condition.
Rob Henderson, a consultant ophthalmologist at GOSH, noted that even small improvements in vision can make a substantial difference for families navigating life with LCA. He emphasized the importance of developing outcome-measurement tools that work across different age groups, given how variable pediatric vision testing can be.
The research is not a cure for LCA, but it confirms that early intervention provides the strongest functional outcomes — a finding that will shape how clinicians counsel families newly receiving an LCA diagnosis.
A Broader Wave of Gene Therapy Reaching Children
Saffie’s story sits within a broader 2026 trend in genetic medicine, in which gene therapies for rare inherited conditions are increasingly reaching pediatric patients. The category has expanded across hearing, vision, neurological, and metabolic disorders, with regulators in multiple jurisdictions approving treatments that would have been considered science fiction a decade ago.
Among the most notable recent advances, Regeneron’s gene therapy for genetic hearing loss became the first treatment of its kind approved in its category — another marker of how the field is moving beyond clinical trials and into routine availability for children with rare diagnoses.
For families navigating an LCA diagnosis specifically, the accessibility of Luxturna through the NHS has been a meaningful development. Treatments of this scale can carry significant cost barriers in many healthcare systems, and the availability of the therapy on the NHS removed one of the most consequential obstacles for the Sandford family.
A Family’s “Magic Wand” Moment
For the Sandfords, the headline is simpler than any clinical summary. Saffie can now see her parents’ faces in the dark for the first time. She has been able to join her family for evenings out, trick-or-treating, and school activities that would have been off-limits without the treatment.
“It’s like they have waved a magic wand and given Saffie her sight back,” her mother said. “I just don’t think there is a better gift than that.”
The case is one human-scale story in a much larger arc of progress. Gene therapy will not solve every inherited condition, and not every patient will respond as fully as Saffie has. But for one Spider-Man-loving six-year-old in Hertfordshire, the science has already done what once seemed impossible — and her family is determined that her story should give other families facing the same diagnosis reason for hope.
